Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novavax Gets Competitive Shot As Third ’23-’24 COVID-19 Vaccine Provider In US

Oct 05 2023

• By Brenda Sandburg

Novavax COVID-19 vaccine — FDA grants emergency use authorization to Novavax's updated COVID-19 vaccine formulation • Source: Shutterstock

Related Content

Novavax’s ’23-’24 COVID Vaccine Can Bypass Another CDC Cmte Meeting – If FDA Authorizes It

Sep 16 2023

Pediatric Data Concerns Can’t Derail US CDC’s Universal ’23-’24 COVID Vaccine Recommendation

Sep 13 2023

COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics

Jun 16 2023

EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season

Sep 22 2023

Related Companies

Novavax, Inc.

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

United States Coronavirus COVID-19 Vaccines Approvals Regulation BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window